Yu Wang; Guangchao Wang; Yunping Ma; Jinglei Teng; Yan Wang; Yongping Cui; Yan Dong; Shujuan Shao; Qimin Zhan; Xuefeng Liu

doi:10.21147/j.issn.1000-9604.2019.04.05

Chin J Cancer Res> 2019, Vol. 31> Issue(4) : 609-619

Citation: Wang Y, Wang G, Ma Y, Teng J, Wang Y, Cui Y, Dong Y, Shao S, Zhan Q, Liu X. FAT1, a direct transcriptional target of E2F1, suppresses cell proliferation, migration and invasion in esophageal squamous cell carcinoma. Chin J Cancer Res 2019;31(4):609-619. doi: 10.21147/j.issn.1000-9604.2019.04.05 shu

FAT1, a direct transcriptional target of E2F1, suppresses cell proliferation, migration and invasion in esophageal squamous cell carcinoma

1.
Institute of Cancer Stem Cell, Dalian Medical University, Dalian 116044, China
2.
State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
3.
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Laboratory of Molecular Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China
4.
Shenzhen Peking University-The Hong Kong University of Science and Technology (PKU-HKUST) Medical Center, Peking University Shenzhen Hospital, Shenzhen 518036, China
5.
College of Stomatology, Dalian Medical University, Dalian 116044, China
6.
Key Laboratory of Proteomics, Dalian Medical University, Dalian 116044, China

Correspondence to: Xuefeng Liu. Institute of Cancer Stem Cell, Dalian Medical University, Dalian 116044, China. Email: ixuee@sina.com
Qimin Zhan. Institute of Cancer Stem Cell, Dalian Medical University, Dalian 116044, China; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Laboratory of Molecular Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China. Email: zhanqimin@bjmu.edu.cn
Submitted: Jan 25, 2019
Accepted for publication: Apr 08, 2019

Figures(5) / Tables(2)

Objective: Growing evidence indicates that FAT atypical cadherin 1 (FAT1) has aberrant genetic alterations and exhibits potential tumor suppressive function in esophageal squamous cell carcinoma (ESCC). However, the role of FAT1 in ESCC tumorigenesis remains not well elucidated. The aim of this study was to further investigate genetic alterations and biological functions of FAT1, as well as to explore its transcriptional regulation and downstream targets in ESCC. Methods: The mutations of FAT1 in ESCC were achieved by analyzing a combined study from seven published genomic data, while the copy number variants of FAT1 were obtained from an analysis of our previous data as well as of The Cancer Genome Atlas (TCGA) and Cancer Cell Line Encyclopedia (CCLE) databases using the cBioPortal. The transcriptional regulation of FAT1 expression was investigated by chromatin immunoprecipitation (ChIP) and the luciferase reporter assays. In-cell western, Western blot and reverse transcription-quantitative polymerase chain reaction (RT-qPCR) were used to assess the indicated gene expression. In addition, colony formation and Transwell migration/invasion assays were employed to test cell proliferation, migration and invasion. Finally, RNA sequencing was used to study the transcriptomes. Results: FAT1 was frequently mutated in ESCC and was deleted in multiple cancers. Furthermore, the transcription factor E2F1 occupied the promoter region of FAT1, and depletion of E2F1 led to a decrease in transcription activity and mRNA levels of FAT1. Moreover, we found that knockdown of FAT1 promoted KYSE30 and KYSE150 cell proliferation, migration and invasion; while overexpression of FAT1 inhibited KYSE30 and KYSE410 cell proliferation, migration and invasion. In addition, knockdown of FAT1 led to enrichment of the mitogen-activated protein kinase (MAPK) signaling pathway and cell adhesion process. Conclusions: Our data provided evidence for the tumor suppressive function of FAT1 in ESCC cells and elucidated the transcriptional regulation of FAT1 by E2F1, which may facilitate the understanding of molecular mechanisms of the progression of ESCC.
- E2F1;
- ESCC;
- FAT1;
- tumor suppressor
[1]
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424. doi: 10.3322/caac.21492 [PubMed]

[2]
Arnold M, Soerjomataram I, Ferlay J, et al. Global incidence of oesophageal cancer by histological subtype in 2012. Gut 2015;64:381-7. doi: 10.1136/gutjnl-2014-308124 [PubMed]

[3]
Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin 2016;66:115-32. doi: 10.3322/caac.21338 [PubMed]

[4]
Yang Z, Zeng H, Xia R, et al. Annual cost of illness of stomach and esophageal cancer patients in urban and rural areas in China: A multi-center study. Chin J Cancer Res 2018;30:439-48. doi: 10.21147/j.issn.1000-9604.2018.04.07 [PubMed]

[5]
Ohashi S, Miyamoto S, Kikuchi O, et al. Recent advances from basic and clinical studies of esophageal squamous cell carcinoma. Gastroenterology 2015;149:1700-15. doi: 10.1053/j.gastro.2015.08.054 [PubMed]

[6]
Pennathur A, Gibson MK, Jobe BA, et al. Oesophageal carcinoma. Lancet 2013;381:400-12. doi: 10.1016/S0140-6736(12)60643-6 [PubMed]

[7]
Song Y, Li L, Ou Y, et al. Identification of genomic alterations in oesophageal squamous cell cancer. Nature 2014;509:91-5. doi: 10.1038/nature13176 [PubMed]

[8]
Gao YB, Chen ZL, Li JG, et al. Genetic landscape of esophageal squamous cell carcinoma. Nat Genet 2014;46:1097-102. doi: 10.1038/ng.3076 [PubMed]

[9]
Lin DC, Hao JJ, Nagata Y, et al. Genomic and molecular characterization of esophageal squamous cell carcinoma. Nat Genet 2014;46:467-73. doi: 10.1038/ng.2935 [PubMed]

[10]
Zhang L, Zhou Y, Cheng C, et al. Genomic analyses reveal mutational signatures and frequently altered genes in esophageal squamous cell carcinoma. Am J Hum Genet 2015;96:597-611. doi: 10.1016/j.ajhg.2015.02.017 [PubMed]

[11]
Sawada G, Niida A, Uchi R, et al. Genomic landscape of esophageal squamous cell carcinoma in a japanese population. Gastroenterology 2016;150:1171-82. doi: 10.1053/j.gastro.2016.01.035 [PubMed]

[12]
Sadeqzadeh E, de Bock CE, Thorne RF. Sleeping giants: emerging roles for the fat cadherins in health and disease. Med Res Rev 2014;34:190-221. doi: 10.1002/med.21286 [PubMed]

[13]
Hu X, Zhai Y, Kong P, et al. FAT1 prevents epithelial mesenchymal transition (EMT) via MAPK/ERK signaling pathway in esophageal squamous cell cancer. Cancer Lett 2017;397:83-93. doi: 10.1016/j.canlet.2017.03.033 [PubMed]

[14]
Hu X, Zhai Y, Shi R, et al. FAT1 inhibits cell migration and invasion by affecting cellular mechanical properties in esophageal squamous cell carcinoma. Oncol Rep 2018;39:2136-46. doi: 10.3892/or.2018.6328 [PubMed]

[15]
Tanoue T, Takeichi M. Mammalian Fat1 cadherin regulates actin dynamics and cell-cell contact. J Cell Biol 2004;165:517-28. doi: 10.1083/jcb.200403006 [PubMed]

[16]
Moeller MJ, Soofi A, Braun GS, et al. Protocadherin FAT1 binds Ena/VASP proteins and is necessary for actin dynamics and cell polarization. EMBO J 2004;23:3769-79. doi: 10.1038/sj.emboj.7600380 [PubMed]

[17]
Hou R, Liu L, Anees S, et al. The Fat1 cadherin integrates vascular smooth muscle cell growth and migration signals. J Cell Biol 2006;173:417-29. doi: 10.1083/jcb.200508121 [PubMed]

[18]
Morris LG, Kaufman AM, Gong Y, et al. Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation. Nat Genet 2013;45:253-61. doi: 10.1038/ng.2538 [PubMed]

[19]
Valletta D, Czech B, Spruss T, et al. Regulation and function of the atypical cadherin FAT1 in hepatocellular carcinoma. Carcinogenesis 2014;35:1407-15. doi: 10.1093/carcin/bgu054 [PubMed]

[20]
Dikshit B, Irshad K, Madan E, et al. FAT1 acts as an upstream regulator of oncogenic and inflammatory pathways, via PDCD4, in glioma cells. Oncogene 2013;32:3798-808. doi: 10.1038/onc.2012.393 [PubMed]

[21]
de Bock CE, Ardjmand A, Molloy TJ, et al. The Fat1 cadherin is overexpressed and an independent prognostic factor for survival in paired diagnosis-relapse samples of precursor B-cell acute lymphoblastic leukemia. Leukemia 2012;26:918-26. doi: 10.1038/leu.2011.319 [PubMed]

[22]
Trimarchi JM, Lees JA. Sibling rivalry in the E2F family. Nat Rev Mol Cell Biol 2002;3:11-20. doi: 10.1038/nrm714 [PubMed]

[23]
Iaquinta PJ, Lees JA. Life and death decisions by the E2F transcription factors. Curr Opin Cell Biol 2007;19:649-57. doi: 10.1016/j.ceb.2007.10.006 [PubMed]

[24]
Castillo DS, Campalans A, Belluscio LM, et al. E2F1 and E2F2 induction in response to DNA damage preserves genomic stability in neuronal cells. Cell Cycle 2015;14:1300-14. doi: 10.4161/15384101.2014.985031 [PubMed]

[25]
Johnson DG, Schwarz JK, Cress WD, et al. Expression of transcription factor E2F1 induces quiescent cells to enter S phase. Nature 1993;365:349-52. doi: 10.1038/365349a0 [PubMed]

[26]
Qin XQ, Livingston DM, Kaelin WG, Jr., et al Deregulated transcription factor E2F-1 expression leads to S-phase entry and p53-mediated apoptosis. Proc Natl Acad Sci U S A 1994;91:10918-22. doi: 10.1073/pnas.91.23.10918 [PubMed]

[27]
Hollern DP, Honeysett J, Cardiff RD, et al. The E2F transcription factors regulate tumor development and metastasis in a mouse model of metastatic breast cancer. Mol Cell Biol 2014;34:3229-43. doi: 10.1128/MCB.00737-14 [PubMed]

[28]
Nahle Z, Polakoff J, Davuluri RV, et al. Direct coupling of the cell cycle and cell death machinery by E2F. Nat Cell Biol 2002;4:859-64. doi: 10.1038/ncb868 [PubMed]

[29]
Gomez-Manzano C, Mitlianga P, Fueyo J, et al. Transfer of E2F-1 to human glioma cells results in transcriptional up-regulation of Bcl-2. Cancer Res 2001;61:6693-7. [PubMed]

[30]
Bertoli C, Skotheim JM, de Bruin RA. Control of cell cycle transcription during G1 and S phases. Nat Rev Mol Cell Biol 2013;14:518-28. doi: 10.1038/nrm3629 [PubMed]

[31]
Dick FA, Rubin SM. Molecular mechanisms underlying RB protein function. Nat Rev Mol Cell Biol 2013;14:297-306. doi: 10.1038/nrm3567 [PubMed]

[32]
Bieda M, Xu X, Singer MA, et al. Unbiased location analysis of E2F1-binding sites suggests a widespread role for E2F1 in the human genome. Genome Res 2006;16:595-605. doi: 10.1101/gr.4887606 [PubMed]

[33]
Huang da W, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 2009;37:1-13. doi: 10.1093/nar/gkn923 [PubMed]

[34]
Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009;4:44-57. doi: 10.1038/nprot.2008.211 [PubMed]

[35]
Kanehisa M, Sato Y, Furumichi M, et al. New approach for understanding genome variations in KEGG. Nucleic Acids Res 2019;47:D590-D595. doi: 10.1093/nar/gky962 [PubMed]

[36]
Du P, Huang P, Huang X, et al. Comprehensive genomic analysis of oesophageal squamous cell carcinoma reveals clinical relevance. Sci Rep 2017;7:15324. doi: 10.1038/s41598-017-14909-5 [PubMed]

[37]
Cancer Genome Atlas Research Network, Analysis Working Group: Asan University, BC Cancer Agency, et al. Integrated genomic characterization of oesophageal carcinoma. Nature 2017;541:169-175. doi: 10.1038/nature20805 [PubMed]

[38]
Qin HD, Liao XY, Chen YB, et al. Genomic characterization of esophageal squamous cell carcinoma reveals critical genes underlying tumorigenesis and poor prognosis. Am J Hum Genet 2016;98:709-27. doi: 10.1016/j.ajhg.2016.02.021 [PubMed]

[39]
Agrawal N, Jiao Y, Bettegowda C, et al. Comparative genomic analysis of esophageal adenocarcinoma and squamous cell carcinoma. Cancer Discov 2012;2:899-905. doi: 10.1158/2159-8290.CD-12-0189 [PubMed]

[40]
Cancer Genome Atlas Research Network, Weinstein JN, Collisson EA, et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet 2013;45:1113-20. doi: 10.1038/ng.2764 [PubMed]

[41]
Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013;6:pl1. doi: 10.1126/scisignal.2004088 [PubMed]

[42]
Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012;2:401-4. doi: 10.1158/2159-8290.CD-12-0095 [PubMed]

[43]
Barretina J, Caponigro G, Stransky N, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012;483:603-7. doi: 10.1038/nature11003 [PubMed]

[44]
Consortium ENCODE Project. An integrated encyclopedia of DNA elements in the human genome. Nature 2012;489:57-74. doi: 10.1038/nature11247 [PubMed]

[45]
Yamasaki L, Bronson R, Williams BO, et al. Loss of E2F-1 reduces tumorigenesis and extends the lifespan of Rb1(+/-)mice. Nat Genet 1998;18:360-4. doi: 10.1038/ng0498-360 [PubMed]

[46]
Russell JL, Weaks RL, Berton TR, et al. E2F1 suppresses skin carcinogenesis via the ARF-p53 pathway. Oncogene 2006;25:867-76. doi: 10.1038/sj.onc.1209120 [PubMed]

[47]
Yamasaki L, Jacks T, Bronson R, et al. Tumor induction and tissue atrophy in mice lacking E2F-1. Cell 1996;85:537-48. doi: 10.1016/S0092-8674(00)81254-4 [PubMed]

[48]
Conner EA, Lemmer ER, Omori M, et al. Dual functions of E2F-1 in a transgenic mouse model of liver carcinogenesis. Oncogene 2000;19:5054-62. doi: 10.1038/sj.onc.1203885 [PubMed]

[49]
Johnson JL, Pillai S, Pernazza D, et al. Regulation of matrix metalloproteinase genes by E2F transcription factors: Rb-Raf-1 interaction as a novel target for metastatic disease. Cancer Res 2012;72:516-26. doi: 10.1158/0008-5472.CAN-11-2647 [PubMed]

[50]
Wu J, Jin YJ, Calaf GM, et al. PAC1 is a direct transcription target of E2F-1 in apoptotic signaling. Oncogene 2007;26:6526-35. doi: 10.1038/sj.onc.1210484 [PubMed]

[51]
Burotto M, Chiou VL, Lee JM, et al. The MAPK pathway across different malignancies: a new perspective. Cancer 2014;120:3446-56. doi: 10.1002/cncr.28864 [PubMed]

[52]
Cargnello M, Roux PP. Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol Mol Biol Rev 2011;75:50-83. doi: 10.1128/MMBR.00031-10 [PubMed]

[53]
Qin X, Zheng S, Liu T, et al. Roles of phosphorylated JNK in esophageal squamous cell carcinomas of Kazakh ethnic. Mol Carcinog 2014;53:526-36. doi: 10.1002/mc.22004 [PubMed]

[54]
Gavine PR, Wang M, Yu D, et al. Identification and validation of dysregulated MAPK7 (ERK5) as a novel oncogenic target in squamous cell lung and esophageal carcinoma. BMC Cancer 2015;15:454. doi: 10.1186/s12885-015-1455-y [PubMed]

[55]
Guo JC, Xie YM, Ran LQ, et al. L1CAM drives oncogenicity in esophageal squamous cell carcinoma by stimulation of ezrin transcription. J Mol Med (Berl) 2017;95:1355-1368. doi: 10.1007/s00109-017-1595-4 [PubMed]

[56]
Higuchi K, Inokuchi M, Takagi Y, et al. Cadherin 5 expression correlates with poor survival in human gastric cancer. J Clin Pathol 2017;70:217-221. doi: 10.1136/jclinpath-2016-203640 [PubMed]

[57]
Tischler V, Pfeifer M, Hausladen S, et al. L1CAM protein expression is associated with poor prognosis in non-small cell lung cancer. Mol Cancer 2011;10:127. doi: 10.1186/1476-4598-10-127 [PubMed]

[58]
Fry SA, Sinclair J, Timms JF, et al. A targeted glycoproteomic approach identifies cadherin-5 as a novel biomarker of metastatic breast cancer. Cancer Lett 2013;328:335-44. doi: 10.1016/j.canlet.2012.10.011 [PubMed]
1. [1]
  Wei Gong, Jiancheng Xu, Guangchao Wang, Dan Li, Qimin Zhan. ZNF292 suppresses proliferation of ESCC cells through ZNF292/SKP2/P27 signaling axis. Chin J Cancer Res, 2021, 33(6): 637-648. doi: 10.21147/j.issn.1000-9604.2021.06.01
2. [2]
  Mengmeng Feng, Shuqin Jia. Dual effect of WISP-1 in diverse pathological processes. Chin J Cancer Res, 2016, 28(6): 553-560. doi: 10.21147/j.issn.1000-9604.2016.06.01
3. [3]
  Xie Zhang, Bowei Yin, Fangfang Zhu, Guochang Huang, Hong Li. A PTEN translational isoform has PTEN-like activity. Chin J Cancer Res, 2015, 27(5): 524-532. doi: 10.3978/j.issn.1000-9604.2015.10.03
4. [4]
  Sebastian Mueller. Pharmacological blockage of CYP2E1 and alcohol-mediated liver cancer: is the time ready?. Chin J Cancer Res, 2013, 25(3): 269-271. doi: 10.3978/j.issn.1000-9604.2013.05.01
5. [5]
  Xiu-lan Su, Ba Bin, Hong-wei Cui, Mei-rong Ran. Cytochrome P450 2E1 RsaI/PstI and DraI Polymorphisms Are Risk Factors for Lung Cancer in Mongolian and Han Population in Inner Mongolia. Chin J Cancer Res, 2011, 23(2): 107-111. doi: 10.1007/s11670-011-0107-2
6. [6]
  Guo-yang Sun, Jun-xia Wu, Jian-sheng Wu, Yu-ting Pan, Rong Jin. Caveolin-1, E-cadherin and β-catenin in Gastric Carcinoma, Precancerous Tissues and Chronic Non-atrophic Gastritis. Chin J Cancer Res, 2012, 24(1): 23-28. doi: 10.1007/s11670-012-0023-0
7. [7]
  Shan Gao, Peter A. Andreasen. DNA Methylation Profiles of Protease Nexin 1 (SERPINE2) Gene in Human Cell Lines. Chin J Cancer Res, 2011, 23(2): 92-98. doi: 10.1007/s11670-011-0092-5
8. [8]
  Shidong Wang, Tingting Ren, Yi Huang, Xing Bao, Kunkun Sun, Danhua Shen, Wei Guo. BMPR2 and HIF1-α overexpression in resected osteosarcoma correlates with distant metastasis and patient survival. Chin J Cancer Res, 2017, 29(5): 447-454. doi: 10.21147/j.issn.1000-9604.2017.05.09
9. [9]
  Manhua Ding, Liang Liu, Chengxi Hu, Yi Liu, Yun Qiao, Xiaodong Jiang. Expression of VEGFR2 and NRP-1 in non-small cell lung cancer and their clinical significance. Chin J Cancer Res, 2014, 26(6): 669-677. doi: 10.3978/j.issn.1000-9604.2014.12.04
10. [10]
  Hongyu Xiang, Ling Xin, Qian Liu, Hong Zhang, Shuang Zhang, Jingming Ye, Yuanjia Cheng, Ting Li, Yinhua Liu, Ling Xu. Clinicopathological analysis of early-stage breast cancer patients that meet indications for BRCA1/2 genetic testing. Chin J Cancer Res, 2020, 32(2): 163-174. doi: 10.21147/j.issn.1000-9604.2020.02.04
11. [11]
  Duo You, Danfeng Du, Xueke Zhao, Xinmin Li, Minfeng Ying, Xun Hu. Mitochondrial malic enzyme 2 promotes breast cancer metastasis via stabilizing HIF-1α under hypoxia. Chin J Cancer Res, 2021, 33(3): 308-322. doi: 10.21147/j.issn.1000-9604.2021.03.03
12. [12]
  Jiawang Wei, Huixia Feng, Weiwei Xiao, Qiaoxuan Wang, Bo Qiu, Shiliang Liu, Meiling Deng, Lixia Lu, Hui Chang, Yuanhong Gao. Cycle number of neoadjuvant chemotherapy might influence survival of patients with T1-4N2-3M0 nasopharyngeal carcinoma. Chin J Cancer Res, 2018, 30(1): 51-60. doi: 10.21147/j.issn.1000-9604.2018.01.06
13. [13]
  Ahmad Ameri, Asdollah Alidoosti, Seyed Yousef Hosseini, Mohammad Parvin, Mohammad Hasan Emranpour, Farnaz Taslimi, Eisa Salehi, Pedram Fadavip. Prognostic Value of Promoter Hypermethylation of Retinoic Acid Receptor Beta (RARB) and CDKN2 (p16/MTS1) in Prostate Cancer. Chin J Cancer Res, 2011, 23(4): 306-311. doi: 10.1007/s11670-011-0306-x
14. [14]
  Jingyan Xu, Min Zhou, Jian Ouyang, Jing Wang, Qiguo Zhang, Yong Xu, Yueyi Xu, Qian Zhang, Xihui Xu, Hui Zeng. Gambogic acid induces mitochondria-dependent apoptosis by modulation of Bcl-2 and Bax in mantle cell lymphoma JeKo-1 cells. Chin J Cancer Res, 2013, 25(2): 183-191. doi: 10.3978/j.issn.1000-9604.2013.02.06
15. [15]
  . Corrigendum to Clinicopathological analysis of early-stage breast cancer patients that meet indications for BRCA1/2 genetic testing. Chin J Cancer Res, 2020, 32(3): 414-. doi: 10.21147/j.issn.1000-9604.2020.03.13
16. [16]
  Huaying An, Xiao Ma, Mingyi Liu, Xiaotong Wang, Xundong Wei, Wei Yuan, Jie Ma. Stomatin plays a suppressor role in non-small cell lung cancer metastasis. Chin J Cancer Res, 2019, 31(6): 930-944. doi: 10.21147/j.issn.1000-9604.2019.06.09
17. [17]
  Sheng-Ming Deng, Wei Zhang, Bin Zhang, Yi-Wei Wu. Assessment of tumor response to chemotherapy in patients with breast cancer using ¹⁸F-FLT: a meta-analysis. Chin J Cancer Res, 2014, 26(5): 517-524. doi: 10.3978/j.issn.1000-9604.2014.08.17
18. [18]
  Lei Fu, Ying Zhu, Wang Jing, Dong Guo, Li Kong, Jinming Yu. Incorporation of circulating tumor cells and whole-body metabolic tumor volume of ¹⁸F-FDG PET/CT improves prediction of outcome in IIIB stage small-cell lung cancer. Chin J Cancer Res, 2018, 30(6): 596-604. doi: 10.21147/j.issn.1000-9604.2018.06.04
19. [19]
  Xiangqi Liu, Xiaomei Lao, Lizhong Liang, Sien Zhang, Kan Li, Guiqing Liao, Yujie Liang. Neck observation versus elective neck dissection in management of clinical T1/2N0 oral squamous cell carcinoma: a retrospective study of 232 patients. Chin J Cancer Res, 2017, 29(3): 179-188. doi: 10.21147/j.issn.1000-9604.2017.03.03
20. [20]
  Ji Xia, Qiang Luo, Shengbin Huang, Fuquan Jiang, Lin Wang, Guanghui Wang, Jingjing Xie, Jie Liu, Yang Xu. Alisol B 23-acetate-induced HepG2 hepatoma cell death through mTOR signaling-initiated G₁ cell cycle arrest and apoptosis: A quantitative proteomic study. Chin J Cancer Res, 2019, 31(2): 375-388. doi: 10.21147/j.issn.1000-9604.2019.02.12
cjcr-31-4-liuxuefeng——Supplements.pdf

PDF

Get Citation

Metrics

Abstract Views(1168)
HTML views(1842)
PDF Downloads(129)
Cited by(0)

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142